FDA Approves Merck ’s Keytruda (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer

Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients Approval marks third FDA-approved indication for Keytruda in cervical cancer and 39th indication for Keytruda in the US RAHWAY,...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news